Donepezil HCl

Producer:Shaanxi Ark Pharmaceutical Co., Ltd., established in 1998, covers an area of 44000 square meters, a construction area of 10000 square meters, a purification area of 2500 square meters and a greening area of 23000 square meters. There are four production workshops: solid workshop, extraction workshop, pretreatment workshop and chemical synthesis workshop, and three production lines of capsule, tablet and API. The company's solid workshop passed GMP certification for the first time in 2003. It is the first batch of pharmaceutical enterprises in Shaanxi Province to pass GMP certification.

Staff size:100-199 persons
Registered capital:RMB 7 million 784 thousand and 900  

Producer:Tianjin Lisheng Pharmaceutical Co., Ltd. was founded in 1951. The main products are Chinese and Western medicine tablets, hard capsules, granules, dropping pills and APIs. Sales cover the whole country, and some products are exported to Japan, Australia, South Korea, Europe, America and Southeast Asia.

At present, Lisheng's products have covered 14 categories and 108 product specifications, mainly involving the production of tablets, capsules, dropping pills and other dosage forms as well as APIs. Among them, 60 varieties have entered the national medical insurance catalogue, 24 varieties and 28 product specifications have entered the national essential drug catalogue.

Staff size:About 1700 persons

Registered capital:RMB 182 million 500 thousand

Producer:Founded in 2001, Zein Biotechnology Co., Ltd. (formerly Chongqing Zein Pharmaceutical Co., Ltd.) has built a CMO industrial service platform with Changshou API production base and Jinfeng preparation production base as the core. Both bases are built in accordance with the new version of China GMP, international cGMP and the latest safety and environmental protection standards. Changshou API production base covers an area of 82000 square meters, and Jinfeng preparation production base covers an area of 49000 square meters. The production capacity of API exceeds 100 tons, and the preparation production line covers normal release and slow-release controlled-release capsules, granules, tablets and other dosage forms.

Producer:Shandong Luoxin Pharmaceutical Group Hengxin Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Luoxin Pharmaceutical Group Co., Ltd.

Luoxin Pharmaceutical Group Co., Ltd. is a large pharmaceutical enterprise group integrating drug R & D, production, trade and medical and health services.

At present, Luoxin Pharmaceutical Group Co., Ltd. has four manufacturing bases, including more than 50 production lines, including powder injection, lyophilized powder injection, solid preparation (including cephalosporins), spray, aerosol, pre encapsulation, large capacity injections, small volume injections, chemical raw materials, cephalosporins, and so on. There are more than ten dosage forms and more than 300 product specifications on the market. There are 48 national new drugs. The company can produce 1 billion powder injections, 500 million freeze-dried powder injections, 400 million large bottles of injections (bags), 500 million small volume injections, 7 billion tablets, 2 billion capsules, 300 million capsules, 80 million dry suspensions, 300 tons of micro pills, 1000 tons of raw materials, 30 million aerosol cans, spray ingredients, and pre encapsulated branches.

Staff size:RMB 50 million

Registered capital:700-799 persons

Producer:Zhejiang Hisun Pharmaceutical Co., Ltd. was founded in 1956. In 2000, Hisun issued A-shares in Shanghai stock exchange, but it continues to remain a state-owned enterprise. Hisun is one of the largest antibiotics and anti-tumor drug production bases in the country. It has won several titles, including first batch of innovative enterprises, national technology innovation demonstration enterprises, and "National Industrial Brand Demonstration Enterprise” of the Chinese Ministry of Industry and Information Technology. 

Hisun began as a small chemical factory and entered the pharmaceutical field in the early 1970s. Since its founding over 60 years ago in 1956, Hisun has amassed a total asset worth of 21.8 billion RMB. While Hisun is primarily engaged in the R&D, manufacturing, and sales and marking of API and final dosage forms of chemical and biological drugs, its core business has extended to include branded generic drugs, biosimilarst and other innovative drugs. 

Staff size:About 9000 persns

Registered capital:RMB 1 billion 169 million